Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/9/2017
SIETES contiene 92005 citas

 1 a 20 de 26 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzlez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf 2017;26:615-24. [Ref.ID 101961]
2. Cita con resumen
Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 2017;73:105-13. [Ref.ID 101939]
3.Enlace a cita original Cita con resumen
Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]
4. Cita con resumen
Trifirò G, de Ridder M, Sultana J, Oteri A, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Molokhia M, Diemberger I, Sturkenboom M. Use of azithromycin and risk of ventricular arrhytmia. CMAJ 2017;189:E560-8. [Ref.ID 101536]
5.Tiene citas relacionadas Cita con resumen
Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, on behalf of the Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. [Ref.ID 100756]
6.Enlace a cita original Cita con resumen
Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, Poluzzi E, De Ponti F, Garbe E, Schink T, Trifirò G. Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol 2016;82:487-97. [Ref.ID 100690]
7.Enlace a cita original
Barrenberg E, Garbe E. Use of over-the counter (OTC) drugs and perceptions of OTC drug safety among German adults. Eur J Clin Pharmacol 2015;71:1389-96. [Ref.ID 99626]
8.Enlace a cita original Cita con resumen
Huber M, Andersohn F, Bronder E, Klimpel A, Thomae M, Konzen Ch, Meyer O, Salama A, Schrezenmeier H, Hildebrandt M, Späth-Schawalbe E, Grüneisen A, Kreutz R, Garbe E. Drug-induced agranulocytosis in the Berlin case–control surveillance study. Eur J Clin Pharmacol 2014;70:339-45. [Ref.ID 97278]
9.Enlace a cita original
Valkhoff VE, Schade R, Jong GW, Romio S, Schuemie MJ, Arfe A, Garbe E, Herings R, Lucchi S, Picelli G, Schink T, Straatman H, Villa M, Kuipers EJ, Sturkenboom MCJM, and on behalf of the investigators of the safety of non-steroidal anti-inflammatory drugs (SOS) project. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms an which study designs do we need to assess safety issues?. BMC Pediatrics 2013;13:192. [Ref.ID 96743]
10. Cita con resumen
Garbe E, Andersohn F, Bronder E, Salama A, Klimpel A, Thomae M, Schrezenmeier H, Hildebrandt M, Späth-Schwalbe E, Grüneisen A, Meyer O, Kurtal H. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2012;68:821-32. [Ref.ID 92827]
11. Cita con resumen
Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;341:83. [Ref.ID 88872]
12. Cita con resumen
Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010;75:335-40. [Ref.ID 88791]
13.Tiene citas relacionadas Cita con resumen
Andersohn F, Garbe E. Agranulocytosis induced by nonchemotherapy drugs. In response. Ann Intern Med 2008;148:320-1. [Ref.ID 82257]
14.Tiene citas relacionadas
Scharnetzky E, Schill W, Garbe E. Long-term mortality associated with aprotinin following coronary artery bypass graft surgery. JAMA 2007;297:2475. [Ref.ID 80381]
15.Tiene citas relacionadas Cita con resumen
Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-65. [Ref.ID 80061]
16.Tiene citas relacionadas Cita con resumen
Schade R, Andersohn F, Garbe E. Dopamine agonists and valvular heart disease. Dr. Schade and colleagues reply. N Engl J Med 2007;356:1678. [Ref.ID 79840]
Garbe E, Andersohn F. Contraindication labelling changes in the United States and Germany. Eur J Clin Pharmacol 2007;63:87-93. [Ref.ID 79052]
18.Tiene citas relacionadas Cita con resumen
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. [Ref.ID 78772]
19.Tiene citas relacionadas
Garbe E, Suissa S. Risks of postmenopausal hormone replacement. JAMA 2002;288:2822. [Ref.ID 64423]
20. Cita con resumen
Follmann M, Heinemann LAJ, Dipl-Stat AB, Garbe E. Treatment with potentially hepatotoxic drugs and the risk of hepatocellular carcinoma: results of a European case-control study. Pharmacoepidemiol Drug Saf 2000;9:417-22. [Ref.ID 53259]
Seleccionar todas
 1 a 20 de 26 siguiente >>